PolTREG S.A.

At PolTREG, we are very excited to announce we have received a patent in the US protecting an important part of our business: the manufacturing of T-regulatory cells (T-regs) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. “The decision by the US Patent and Trademark Office (USPTO) complements our large intellectual property portfolio in the US and EU. It paves the way for rapid commercialization of our cell therapies,” said PolTREG CEO Prof Piotr Trzonkowski. Many of PolTREG’s patents are primary in the field, given that our team performed first-in-human trials with Treg cell therapies in graft-vs-host disease in 2007-2009. We now have 17 years’ experience with patients. We have so far successfully treated 27 Type-1 Diabetes patients commercially under a local hospital exemption program. #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes

PolTREG on 8 MAY showed again what a hub of scientific expertise it is, when Dr Magdalena Piotrowska-Mieczkowska – one of our R&D leaders - successfully defended her PhD thesis, receiving the title with honours for her work: ‘Epigenetic changes in the functioning of immune cells – implications for cellular therapy in type 1 diabetes’. The tutor was PolTREG Chief Scientific Officer dr hab. Dorota Iwaszkiewicz-Grzes. Many thanks also to dr Mateusz Gliwiński from the Medical University of Gdansk, who helped a lot in this mission. The company is already using the results of Magdalena’s thesis in developing our engineered Tregs, which in the future will hopefully improve the life of many patients with type-1 diabetes.   #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes

Dan Shelly PhD presented PolTREG, and Prof Piotr Trzonkowski joined in the disucssion at an editorial webinar by BioPharma-Reporter, a widely read online publication. Also on the panel was Sharon Barkatullah, PhD PhD, head of analytical development at the Cell and Gene Therapy Catapult, a London-based centre of excellence that brings together academia and the pharmaceutical industry to help bring innovative therapies to market, as well as Daniel Gibson, Director of Cell and Gene Therapy Services at Anthony Nolan, a non-profit organisation helping to save the lives of patients with blood cancer. Thank you Isabel Cameron for moderating the panel. The full recording is available for everybody to see here: https://shorturl.at/ejvB5 (just sign up at no cost). #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

Government grants enable PolTREG to develop breakthrough technologies. PolTREG was granted PLN 31.7 M ($7.8 M) from the Medical Research Agency (Agencja Badań Medycznych) in January 2023 to develop a cell therapy for presymptomatic Type-1 diabetes. PolTREG has just completed a long-term post-trial study of 51 patients recruited from previous clinical trials, monitored over a period of at least 5 years after being treated with Treg cells. The study was into the long-term safety, and the company will develop a database with the findings. PolTREG has more than 17 years of experience treating patients. We have administered Treg cells to more than 100 people over that period, either in hospital exemption procedures or in clinical trials. #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes #diabetes #grants #type1diabetes

PolTREG is developing every possible Treg therapy for auto-immune diseases: from naturally occuring polyclonal cells to next-generation engineered cells. It can manufacture these cells – and transport them across Europe – within 24 hours from its own state-of-the-art facility in Poland. That gives PolTREG a unique competitive advantage. Dan Shelly PhD, Chief Business Development Officer, presented this view for the company at a conference organised by INNODIA, a network of scientists, pharmaceutical companies and patient organisations for Type-1 Diabetes. Chief Executive Officer Prof Piotr Trzonkowski was also at the event, supported by the University of KU Leuven, in Belgium. #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

It’s another busy week for PolTREG. Chief Business Development Officer Dan Shelly will present the company in Rome on Wednesday, where he will be addressing an audience of senior executives and decision-makers in the cell and gene therapy sector at the Meeting on the Med. https://lnkd.in/eUTEuU7 And Chief Executive Officer Piotr Trzonkowski will show how the company is already helping diabetes patients at the Innodia networking event in Louvain, Belgium, on Friday. Innodia is a global partnership between academic institutions, industrial partners, a small-sized enterprise and patient organisations, bringing their knowledge and experience together with one common goal: “to fight Type-1 Diabetes” https://www.innodia.eu/ #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

PolTREG has identified a promising efficacy biomarker that may facilitate monitoring the health of Type-1 diabetes patients treated with T-regulatory cells. This is described in a study, published in the prestigious magazine International Immunopharmacology. “This peer-reviewed scientific publication adds to our growing excitement about the potential of polyclonal Treg therapies,” Chief Executive Officer Piotr Trzonkowski said in a press release about the publication. The article, which Prof Trzonkowski co-authored, presented data suggesting that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset Type-1 diabetes patients, which had received Treg therapy in combination with rituximab. PolTREG has treated more than 100 patients with cell therapies at its facility over the past 17 years. This has given the company a wealth of data, and unrivalled experience with how Type-1 Diabetes and other autoimmune diseases respond to treatment. For a link to the press release, click here: https://lnkd.in/dat2hSgT To read the article, click here: https://lnkd.in/dPF-Yknf #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

Last week was full of exciting events for the PolTREG S.A. team.   CEO Piotr Trzonkowski joined a group of prominent investigators and clinicians at the 6th International Sam Strober Workshop on Clinical Immune Tolerance, held at the prestigious University of Oxford.   Chief Business Officer Mariusz Jablonski attended the #CEBioForum2024 conference in Warsaw, where he took part in a panel discussion focused on cell and gene therapies.   See you at the next events!   #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investmentfunds #investing #diabetes

CEO Piotr Trzonkowski will join the ranks of other leading investigators and clinicians at the 6h International Sam Strober Workshop on Clinical Immune Tolerance at the prestigious University of Oxford. Prof. Trzonkowski will be the first speaker on Tuesday, 26 March, to discuss PolTREG’s experience with diabetes. Did you know that PolTREG has administered Treg cells to more than 100 autoimmune patients in its 17-year history? These therapies are not yet on the market, but patients may receive them under a hospital exemption or in clinical trials. Learn more: https://lnkd.in/d6QNequ2 #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

Two approvals in one week! A few days after receiving the green light to produce cellular therapies for clinical trials, PolTREG has now received approval to treat patients with therapies produced under hospital exemption rule at its state-of-the-art manufacturing facility in Gdansk in Poland. The approval allows patients to receive treatment for diseases such as Type-1 Diabetes with Tregs therapy at the national level before central manufacturing authorization is received. PolTREG has more than 17 years of experience treating patients. We have administered Treg cells to more than 100 people over that period, either in hospital exemption procedures or in clinical trials. #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investmentfunds  #investing #diabetes